Aldosterone synthase (CYP11B2)-344T/C polymorphism and renoprotective response to losartan treatment in diabetic nephropathy

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 66, Issue 3, 2006, Pages 173-180

  Schjoedt, K J ^a   Lajer, M ^a   Andersen, S ^a   Tarnow, L ^a   Rossing, P ^a   Parving, H H ^a,b  

^a STENO DIABETES CENTER   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

Author keywords

24 h blood pressure; Angiotensin II receptor blockade; GFR; Renin angiotensin aldosterone system

Indexed keywords

ALDOSTERONE SYNTHASE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; LOSARTAN;

ADULT; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CLINICAL ARTICLE; DIABETIC NEPHROPATHY; DOSE RESPONSE; DRUG RESPONSE; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; GLOMERULUS FILTRATION RATE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FUNCTION; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC BLOOD PRESSURE;

ADULT; ALBUMINURIA; ALDOSTERONE SYNTHASE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION; LOSARTAN; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; RENIN-ANGIOTENSIN SYSTEM; TIME FACTORS;

EID: 33745728433     PISSN: 00365513     EISSN: 15027686     Source Type: Journal    
DOI: 10.1080/00365510600548702     Document Type: Article

References (16)

1. Hommel E, Parving H-H, Mathiesen ER, Edsberg B, Nielsen MD, Giese J. Effect of captopril on kidney function in insulin-dependent diabetic patients with nephropathy. Br Med J 1986;293:466-70.
2. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993;329:1456-62.
3. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60.
4. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving H-H. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.
5. Parving H-H, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-8.
6. Epstein M. Aldosterone and the hypertensive kidney: its emerging role as a mediator of progressive renal dysfunction: a paradigm shift. J Hypertens 2001;19:829-42.
7. Epstein M, Buckalew V, Martinez F, Altamirano J, Roniker B, Kleiman J, et al. Antiproteinuric efficacy of eplerenone, enalapril, and eplerenone/enalapril combination therapy in diabetic hypertensives with microalbuminuria [abstract]. Am J Hypertens 2002;15:A24.
8. Rachmani R, Slavachevsky I, Amit M, Levi Z, Kedar Y, Berla M, et al. The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study. Diabet Med 2004;21:471-5.
9. Sato A, Hayashi K, Naruse M, Saruta T. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003;41:64-8.
10. Davies E, Holloway CD, Ingram MC, Inglis GC, Friel EC, Morrison C, et al. Aldosterone excretion rate and blood pressure in essential hypertension are related to polymorphic differences in the aldosterone synthase gene CYP11B2. Hypertension 1999;33:703-7.
11. Brand E, Chatelain N, Mulatero P, Fery I, Curnow K, Jeunemaitre X, Corvol P, et al. Structural analysis and evaluation of the aldosterone synthase gene in hypertension. Hypertension 1998;32:198-204.
12. Kurland L, Melhus H, Karlsson J, Kahan T, Malmqvist K, Ohman P, et al. Aldosterone synthase (CYP11B2) -344 C/T polymorphism is related to antihypertensive response: result from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus the Atenolol (SILVHIA) Trial. Am J Hypertens 2002;15:389-93.
13. Andersen S, Tarnow L, Cambien F, Rossing P, Juhl TR, Deinum J, et al. Long-term renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype? Diabetes Care 2003;26:1501-6.
14. Kupari M, Hautanen A, Lankinen L, Koskinen P, Virolainen J, Nikkila H, et al. Associations between human aldosterone synthase (CYP11B2) gene polymorphisms and left ventricular size, mass, and function. Circulation 1998;97:569-75.
15. Pojoga L, Gautier S, Blanc H, Guyene TT, Poirier O, Cambien F, et al. Genetic determination of plasma aldosterone levels in essential hypertension. Am J Hypertens 1998;11:856-60.
16. Epstein M. Aldosterone receptor blockade and the role of eplerenone: evolving perspectives. Nephrol Dial Transplant 2003;18:1984-92.